Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Available × INDUSTRY × Carcinoma, Renal Cell × Clear all

Status

Completed 286 Terminated 88 Active not recruiting 70 Recruiting 60 Withdrawn 19 Unknown 16 Not yet recruiting 7 Suspended 4 No longer available 4 Enrolling by invitation 2 Available 1 Approved for marketing 1

Sponsor Class

Study Type

Expanded_access 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Neoplasms 6 Precursor Cell Lymphoblastic Leukemia-Lymphoma 5 Multiple Myeloma 5 Carcinoma, Non-Small-Cell Lung 5 Sarcoma 4 Prostatic Neoplasms 4 Melanoma 4 Lymphoma, Large B-Cell, Diffuse 4 Pancreatic Neoplasms 3 Ovarian Neoplasms 3 Leukemia, Myeloid, Acute 3 Urinary Bladder Neoplasms 2 Stomach Neoplasms 2 Recurrence 2 Primary Myelofibrosis 2 Non-Muscle Invasive Bladder Neoplasms 2 Neoplasm Metastasis 2 Lymphoma, T-Cell, Peripheral 2 Lymphoma, Non-Hodgkin 2 Lymphoma, Follicular 2 Glioblastoma 2 Colorectal Neoplasms 2 Cholangiocarcinoma 2 Carcinoma, Transitional Cell 2 Carcinoma, Hepatocellular 2 Breast Neoplasms 2 Uveal Melanoma 1 Urologic Neoplasms 1 Tuberous Sclerosis 1 Thyroid Neoplasms 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06090331 2025-07-08

89Zr-DFO-girentuximab Expanded Access Program (EAP)

Telix Pharmaceuticals (Innovations) Pty Limited

Carcinoma, Renal Cell

Data powered by HemOnc (CC BY 4.0) Colophon ⚡